This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For more information on key components of a fit-for-purpose, phase-by-phase QMS guidance download Advarra’s whitepaper Steps to Implementing a Quality Management System. The sponsor-initiated IND is conducted by a pharmacompany seeking commercial approval. Q: What must be done to prove oversight?
The demand for an effective drug for nail fungus is high and MOB-015 can achieve a unique market position through its high antifungal effect,” says Anna Ljung, CEO of Moberg Pharma. The following files are available for download: View original content: [link]. SOURCE Moberg Pharma.
CET on November 6, 2020.
Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Phages that can be essentially downloaded and synthesized by anyone, in any location, would solve those problems, he says. There is also a growing body of successful treatments in the U.S.,
Techbio companies have initiated this approach. Now even non-AI native big pharmacompanies take a similar view on using clinical genomics with integrated multimodality. He also develops and presents customised training programmes (both live and virtual) for companies seeking to improve their in- and out-licensing processes.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content